Cocrystal Pharma Files 8-K
Ticker: COCP · Form: 8-K · Filed: Jun 5, 2025 · CIK: 1412486
| Field | Detail |
|---|---|
| Company | Cocrystal Pharma, INC. (COCP) |
| Form Type | 8-K |
| Filed Date | Jun 5, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, regulatory-filing, SEC
TL;DR
Cocrystal Pharma filed a routine 8-K. No major news.
AI Summary
Cocrystal Pharma, Inc. filed an 8-K on June 5, 2025, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or material events beyond the standard reporting requirements.
Why It Matters
This filing indicates Cocrystal Pharma, Inc. is meeting its regulatory reporting obligations with the SEC. It does not disclose new material information that would immediately impact the company's stock.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for regulatory compliance and does not contain any new material information or significant financial events.
Key Players & Entities
- Cocrystal Pharma, Inc. (company) — Registrant
- June 5, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 001-38418 (filing_number) — Commission File Number
- 35-2528215 (ein) — IRS Employer Identification No.
- 19805 N. Creek Parkway (address) — Principal executive offices street
- Bothell, WA (address) — Principal executive offices city and state
- 98011 (zip_code) — Principal executive offices zip code
- (877) 262-7123 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report a Regulation FD Disclosure and to file Financial Statements and Exhibits as required by the SEC.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on June 5, 2025.
What is Cocrystal Pharma, Inc.'s state of incorporation?
Cocrystal Pharma, Inc. is incorporated in Delaware.
What is the company's principal executive office address?
The company's principal executive office is located at 19805 N. Creek Parkway, Bothell, WA 98011.
Does this filing disclose any new material events or financial results?
This filing does not appear to disclose any new material events or specific financial results beyond standard reporting requirements.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 5, 2025 regarding Cocrystal Pharma, Inc. (COCP).